Answer
Patients receiving enfortumab vedotin with clarithromycin, a strong CYP3A4 inhibitor, should be monitored more closely for signs of toxicity.
Sources for this answer
- Padcev 20 mg and 30 mg powder for concentrate for solution for infusionAstellas Pharma Ltd · emc · SmPC §4.5 Interaction with other medicinal products · Version 10Document updated
Sources checked